Location of Repository

Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression

By Martin Michaelis, Janina Geiler, Patrizia Naczk, Patchima Sithisarn, Anke Leutz, Hans Wilhelm Doerr and Jindrich Cinatl

Abstract

Glycyrrhizin is known to exert antiviral and anti-inflammatory effects. Here, the effects of an approved parenteral glycyrrhizin preparation (Stronger Neo-Minophafen C) were investigated on highly pathogenic influenza A H5N1 virus replication, H5N1-induced apoptosis, and H5N1-induced pro-inflammatory responses in lung epithelial (A549) cells. Therapeutic glycyrrhizin concentrations substantially inhibited H5N1-induced expression of the pro-inflammatory molecules CXCL10, interleukin 6, CCL2, and CCL5 (effective glycyrrhizin concentrations 25 to 50 µg/ml) but interfered with H5N1 replication and H5N1-induced apoptosis to a lesser extent (effective glycyrrhizin concentrations 100 µg/ml or higher). Glycyrrhizin also diminished monocyte migration towards supernatants of H5N1-infected A549 cells. The mechanism by which glycyrrhizin interferes with H5N1 replication and H5N1-induced pro-inflammatory gene expression includes inhibition of H5N1-induced formation of reactive oxygen species and (in turn) reduced activation of NFKappaB, JNK, and p38, redox-sensitive signalling events known to be relevant for influenza A virus replication. Therefore, glycyrrhizin may complement the arsenal of potential drugs for the treatment of H5N1 disease

Topics: ddc:610
Year: 2011
OAI identifier: oai:publikationen.ub.uni-frankfurt.de:22582

Suggested articles

Preview

Citations

  1. (2010). A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function.
  2. (2007). Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaBinhibiting activity.
  3. (2008). Analysis of gene expression in human bronchial epithelial cells upon influenza virus infection and regulation by p38 mitogen-activated protein kinase and c-Jun-N-terminal kinase.
  4. (2005). Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus.
  5. (2008). Antiviral drugs for the control of pandemic influenza virus.
  6. (2008). Antiviral effects of Glycyrrhiza species.
  7. (2007). Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans.
  8. (1997). Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.
  9. (2005). Avian influenza A (H5N1) infection in humans.
  10. (2003). Caspase 3 activation is essential for efficient Influenza virus propagation.
  11. (1979). Cell line A549 as a model of the type II pneumocyte. Phospholipid biosynthesis from native and organometallic precursors.
  12. (2009). Confronting the next influenza pandemic with antiinflammatory and immunomodulatory agents: why they are needed and how they might work.
  13. (2006). Cutting edge: apoptosis-regulating signal kinase 1 is required for reactive oxygen speciesmediated activation of IFN regulatory factor 3 by lipopolysaccharide.
  14. (2008). Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.
  15. (2005). Development of antiviral therapy for severe acute respiratory syndrome.
  16. (2006). Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.
  17. (2009). Epidemiologic study of influenza infection in
  18. (2006). Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
  19. (2001). Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events.
  20. (2009). Global transmission of oseltamivir-resistant influenza.
  21. (2010). Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced proinflammatory cytokine and chemokine expression in human macrophages.
  22. (2009). Glycyrrhizin inhibits influenza A virus uptake into the cell.
  23. (1997). Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus.
  24. (2003). Glycyrrhizin, an active component of liquorice roots, and replication of SARSassociated coronavirus.
  25. (2008). H5N1 transmission and disease: observations from the frontlines.
  26. (2007). High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005–2006 season.
  27. (2009). Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam,
  28. (2008). Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the
  29. (2009). Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK.
  30. (2009). Infection of human retinal pigment epithelial cells with influenza A viruses.
  31. (2009). Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.
  32. (2000). Inflammatory responses in influenza A virus infection.
  33. (2008). Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy.
  34. (2003). Inhibition of influenza infection by glutathione.
  35. (2007). Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection.
  36. (2010). N-acetyl-Lcysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.
  37. (2009). Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein.
  38. (2009). Of chickens and men: avian influenza in humans.
  39. (2006). Oxidative stress and redox regulation of lung inflammation in COPD.
  40. (2000). p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells.
  41. (2008). Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response.
  42. (1999). Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection.
  43. (2009). Quantitative analysis of cellular proteome alterations in human influenza A virus-infected mammalian cell lines.
  44. (2006). Reactive oxygen speciesinduced activation of the MAP kinase signaling pathways.
  45. (2007). Reduced sensitivity of influenza A (H5N1) to oseltamivir.
  46. (2008). Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds.
  47. (2005). Role of apoptosis and cytokines in influenza virus morbidity.
  48. (2006). Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection.
  49. (2007). Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.
  50. (2009). Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy.
  51. (2006). The anti-respiratory syncytial virus effect of active compound of Glycyrrhiza GD4 in vitro.
  52. (2005). The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope.
  53. (2008). The pandemic influenza vaccine challenge.
  54. (2007). The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology.
  55. (2007). The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants.
  56. (2007). The threat of avian influenza A (H5N1). Part III: Antiviral therapy.
  57. (2007). The threat of avian influenza A (H5N1). Part IV: Development of vaccines.
  58. (2009). TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.
  59. (2009). Use of oseltamivir in 12 European countries between
  60. (2008). Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.